Tuesday, April 28, 2026 9:22:18 PM
Investor082,
Thanks for reposting that again, but your opinions & predictions are still just baseless rumor. 😶
LP is the largest SHAREHOLDER, so she’s not going to “pull the rug” or act against the best interests of shareholders, including herself.
LP has focused on building prospective value via NWBO’s associations with UCLA, Pittsburgh, Roswell, & King’s College. She has leveraged research funded by peer-reviewed grants & she built, developed, & acquired more assets for the company…
NWBO recently expanded its asset portfolio significantly in 2024 & 2025 with the IP licensing deal of more cell-based technology & the
acquisition of Advent.
✅ DCVax®-L
✅ DCVax®-Direct
✅ Polarized aDC1 Platform
AI Fact-Checking
All foregoing comments relate exclusively to the topic of Northwest Biotherapeutics and its stock. Statements are made in the context of public discussion and are directed solely at the content of claims, forecasts, or interpretations presented therein. Any emphasis in tone or phrasing is used solely to highlight discrepancies, inconsistencies, unsupported conclusions, or areas where additional substantiation may be appropriate or requested in furtherance of the discussion. Nothing herein is intended as commentary on any individual participant, identity, or posting alias.
Thanks for reposting that again, but your opinions & predictions are still just baseless rumor. 😶
LP is the largest SHAREHOLDER, so she’s not going to “pull the rug” or act against the best interests of shareholders, including herself.
LP has focused on building prospective value via NWBO’s associations with UCLA, Pittsburgh, Roswell, & King’s College. She has leveraged research funded by peer-reviewed grants & she built, developed, & acquired more assets for the company…
NWBO recently expanded its asset portfolio significantly in 2024 & 2025 with the IP licensing deal of more cell-based technology & the
acquisition of Advent.
✅ DCVax®-L
✅ DCVax®-Direct
✅ Polarized aDC1 Platform
AI Fact-Checking
All foregoing comments relate exclusively to the topic of Northwest Biotherapeutics and its stock. Statements are made in the context of public discussion and are directed solely at the content of claims, forecasts, or interpretations presented therein. Any emphasis in tone or phrasing is used solely to highlight discrepancies, inconsistencies, unsupported conclusions, or areas where additional substantiation may be appropriate or requested in furtherance of the discussion. Nothing herein is intended as commentary on any individual participant, identity, or posting alias.
Bullish
I am a long NWBO shareholder. Views expressed are my own, and I have no affiliation with the company.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
